U.S. markets closed
  • S&P 500

    3,963.94
    -62.18 (-1.54%)
     
  • Dow 30

    33,849.46
    -497.57 (-1.45%)
     
  • Nasdaq

    11,049.50
    -176.86 (-1.58%)
     
  • Russell 2000

    1,830.96
    -38.23 (-2.05%)
     
  • Crude Oil

    76.54
    -0.70 (-0.91%)
     
  • Gold

    1,740.30
    0.00 (0.00%)
     
  • Silver

    20.90
    -0.02 (-0.07%)
     
  • EUR/USD

    1.0343
    -0.0061 (-0.59%)
     
  • 10-Yr Bond

    3.7030
    +0.0120 (+0.33%)
     
  • GBP/USD

    1.1961
    -0.0130 (-1.08%)
     
  • USD/JPY

    138.9160
    -0.1840 (-0.13%)
     
  • BTC-USD

    16,223.38
    -365.05 (-2.20%)
     
  • CMC Crypto 200

    380.17
    -0.12 (-0.03%)
     
  • FTSE 100

    7,474.02
    -12.65 (-0.17%)
     
  • Nikkei 225

    28,162.83
    -120.20 (-0.42%)
     

Infinity to Participate in Wells Fargo and H.C. Wainwright Investor Conferences

CAMBRIDGE, Mass., August 31, 2022--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that the Company will present and conduct 1-on-1 meetings with investors at the 2022 Wells Fargo Healthcare Conference and H.C. Wainwright 24th Annual Global Investment Conference.

2022 Wells Fargo Healthcare Conference
Date: Friday, September 9, 2022
Time: 8:00 a.m. ET
Speaker: Adelene Perkins, Chief Executive Officer
Format: In-person fireside chat and 1-on-1 meetings
Webcast Registration Link

H.C. Wainwright 24th Annual Global Investment Conference
Date: Monday, September 12, 2022
Time: Presentation available at 7:00 a.m. ET
Speaker: Adelene Perkins, Chief Executive Officer
Format: Virtual company presentation and 1-on-1 meetings
Webcast Registration Link

A replay of the presentations will be available in the Investors/Media section of Infinity's website at www.infi.com for 90 days following the events.

About Infinity and Eganelisib
Infinity Pharmaceuticals, Inc. ("Infinity" or the "Company"), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which is designed to address a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo® is a registered trademark of Bristol Myers Squibb.
Tecentriq® is a registered trademark of Genentech, Inc.
Abraxane® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin® is a registered trademark of Genentech, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220831005151/en/

Contacts

Investor Relations:
Kevin Lui
Real Chemistry
klui@realchemistry.com